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Quantitative gene expression measurements from tumor tissue are frequently compared with matched normal
and/or adjacent tumor tissue expression for diagnostic marker gene selection as well as assessment of the
degree of transcriptional deregulation in cancer. Selection of an appropriate reference gene (RG) or an RG
panel, which varies depending on cancer type, molecular subtypes, and the normal tissues used for interindi-
vidual calibration, is crucial for the accurate quantification of gene expression. Several RG panels have been
suggested in breast cancer for making comparisons among tumor subtypes, cell lines, and benign/malignant
tumors. In this study, expression patterns of 15 widely used endogenous RGs (ACTB, TBP, GAPDH, SDHA,
HPRT, HMBS, B2M, PPIA, GUSB, YWHAZ2, PGK1, RPLP0, PUM1, MRPL19, and RPL41), and three
candidate genes that were selected through analysis of two independent microarray datasets (IL22RA1,
TTC22, ZNF224) were determined in 23 primary breast tumors and their matched normal tissues using qRT-
PCR. Additionally, 18S rRNA, ACTB, and SDHA were tested using randomly primed cDNAs from 13 breast
tumor pairs to assess the rRNA/mRNA ratio. The tumors exhibited significantly lower rRNA/mRNA ratio
when compared to their normals, on average. The expression of the studied RGs in breast tumors did not
exhibit differences in terms of grade, ER, or PR status. The stability of RGs was examined based on two
different statistical models, namely GeNorm and NormFinder. Among the 18 tested endogenous reference
genes, ACTB and SDHA were identified as the most suitable reference genes for the normalization of qRT-
PCR data in the analysis of normal matched tumor breast tissue pairs by both programs. In addition, the
expression of the gelsolin (GSN) gene, a well-known downregulated target in breast tumors, was analyzed
using the two most suitable genes and different RG combinations to validate their effectiveness as a normal-
ization factor (NF). The GSN expression of the tumors used in this study was significantly lower than that
of normals showing the effectivity of using ACTB and SDHA as suitable RGs in this set of tumor–normal
tissue panel. The combinational use of the best performing two RGs (ACTB and SDHA) as a normalization
factor can be recommended to minimize sample variability and to increase the accuracy and resolution of
gene expression normalization in tumor–normal paired breast cancer qRT-PCR studies.
Key words: Real-time quantitative RT-PCR; Endogenous reference genes; Normalization factor; Breast cancer
INTRODUCTION
Real-time quantitative RT-PCR (reverse-transcription
polymerase chain reaction) is one of the most sensitive
and specific methods for quantification of expression at
the mRNA level (1–4). Inclusion of an endogenous ref-
erence gene or genes (RGs) is crucial to standardize ini-
tial RNA quantity to overcome bias originating from
RNA measurement errors, problems with RNA integrity,
and differential cDNA conversion efficiencies (5–7).
Different options exist to quantify expression from the
results of a qRT-PCR run, such as the relative quantifi-
cation by the 2−∆∆Ct method or mRNA copy number esti-
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mation (8). Quantification of a target gene requires the
use of a proper RG whose expression is relatively stable
across samples to estimate the degree of variability
within and among experimental groups as well as to
standardize the expression to a baseline common to all
samples (5–7,9). Nevertheless, numerous studies show
an inherent instability in regard to expression of house-
keeping genes, many of which are still commonly used
as references (10–16).
Analysis of gene expression is fundamental for can-
cer research for the detection of subtle differential ex-
pression between tumor and normal tissues or among
different tumor types. In particular, recent target valida-
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tion and disease diagnostic marker selection studies rely
primarily on gene expression comparisons between tu-
mor–normal pairs (17–21).
Moreover, the use of multiple endogenous RGs sig-
nificantly increases the accuracy of the normalization by
reducing the impact of outliers (5,9). Accordingly, a
plethora of single or combinational usage of two or more
RGs has been recommended for relative quantification
of expression data for various tumor tissue types (22–
29).
Breast cancer is the most common cancer affecting
women worldwide. New high-throughput technologies
have opened the possibility to study the gene expression
profile of the tumors. The validation of differentially ex-
pressed genes using independent methodology such as
qRT-PCR is often desirable. In breast cancer qRT-PCR
studies, different single housekeeping genes have been
used to quantify the expression level of target genes
(30–40). Recently, MRPL19 and PPIA were reported as
a stable RG combination to analyze benign and malig-
nant breast cancer specimens (41). Similarly, Lyng et al.
reported an RG panel comprised of TBP, RPLP0, and
PUM1 for normalizing the gene expression levels across
the ER+ and ER− breast tumors, and normal breast tis-
sues (42).
However, there are yet no systematic studies report-
ing on the expression of commonly used RGs in tumor-
matched normal breast samples.
The aim of this study was to identify a suitable RG(s)
that can be used as a normalization factor (NF) for more
accurate and reliable normalization of paired breast tu-
mor–normal tissue gene expression studies with qRT-
PCR.
We evaluated 18 potential candidate RGs listed in
Table 1 for their expression profile in 23 normal paired
breast tumor tissue specimens. The genes ACTB and
SDHA were calculated as the most stable RGs by two
dedicated validation programs, geNorm and Norm-
Finder. Furthermore, the suitability of these RGs as NF
individually or in combination was validated based on
the relative expression quantification of gelsolin (GSN).
Correlation coefficients between GSN expression values
that were normalized either to a single RG or combina-
tions of RGs in breast tumors were also assessed. We
also determined the expression of 18S rRNA to ACTB
or SDHA mRNA from randomly primed cDNA on a
subset of tumor–normal samples (n = 13 pairs) and
found that tumors exhibited significantly lower rRNA/
mRNA ratio.
The results of the present study showed that using the
geometric mean of the combinations of two of the best
performing RGs as NF can be used to reduce the vari-
ability between tumor samples and their normal counter-




Primary tumor samples and matched normal breast
tissues were obtained from patients (n = 23, mean age
48 years, range 24–74 years) during surgery and imme-
diately snap-frozen in liquid nitrogen and stored at
−80°C until RNA extraction. The frozen tissue samples
were sectioned and mounted on glass slides. The slides
were stained with hematoxylin and eosin for histopatho-
logical examinations. The tumor samples with more than
90% tumor cells and patient-matched tissue pairs with
normal histological examination were included in this
study. These frozen tissues were cut into 5-µM-thick
sections and used for RNA isolation and cDNA synthe-
sis. All the tumor samples had been classified as infil-
trating ductal carcinoma. Tumor grade was determined
according to the Bloom-Richardson score. Eight of the
23 tumors studied were grade 1 and the number of grade
2 and grade 3 tumors was 7 and 8, respectively. Eleven
of the samples were estrogen receptor positive (ER+)
while 10 of them were estrogen receptor negative (ER−).
The number of progesterone positive (PR+) tumors was
11 and that of progesterone negative (PR−) tumors was
10.
The use of the tissue material was approved by the
Research Ethics Committee of Ankara Numune Re-
search and Teaching Hospital and consents were ob-
tained in accordance with the Helsinki Declaration.
RNA Extraction and cDNA Synthesis
The frozen breast specimens were put into Trizol re-
agent (AppliChem, Darmstadt, Germany), disrupted
with a homogenizer, and total RNA was isolated accord-
ing to the manufacturer’s instructions. Genomic DNA
contaminations were removed by on-column DNaseI
treatment (Macharel Nagel, Duren, Germany). The con-
centration of the isolated RNA and the ratio of absor-
bance at 260 nm to 280 nm were measured with the
NanoDrop ND-1000 spectrophotometer (NanoDrop
Technologies, Montchanin, DE, USA) in triplicate. The
mean OD260/280 ratio for RNA samples was 2.03 ± 0.12
(range 1.92–2.15; n = 46). An aliquot of 1 µg total RNA
from each sample was electrophoresed on a 1.2% RNA
agarose gel to confirm integrity of the RNA. First-strand
cDNA was synthesized from 1 µg total RNA using
oligo(dT) or random hexamer primers by using the Re-
vert Aid First strand cDNA synthesis kit (Fermentas,
MD, USA). The random hexamer primed cDNA sam-
ples (n = 13, tumor and normal pair) were used for the
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analysis of 18S rRNA gene expression together with
SDHA and ACTB in the same samples. All cDNAs
were diluted 1:5 times before being used as a PCR tem-
plate and stored at −20°C until further use.
Real-Time Quantitative RT-PCR
Expression levels of 18 RGs [ACTB, GAPD, TBP,
SDHA, HPRT, HMBS, B2M, PPIA, GUSB, YWHAZ,
PGK1, RPL41, PUM1, RPLP0, MRPL19, TTC22,
IL22RA1, ZNF224, and the gelsolin (GSN) gene] were
quantified with qRT-PCR by using the SYBR Green I
dye detection system on the BioRad iCycler Instrument
(BioRad Laboratories, Hercules, CA, USA). In order to
test whether the ratio of the mRNA to rRNA was stable
across tumor and matched normal samples, 18S rRNA,
ACTB, and SDHA genes were quantified with qRT-PCR
by using randomly primed cDNA samples. The primers
were designed to include large intronic sequences be-
tween the forward and reverse pair or designed from
exon–exon boundaries to avoid DNA contamination if
any remained in the RNA samples. The sequences of the
gene-specific primers were put into the blast search to
determine their specificities. None of the primer pairs
showed significant homology to other sequences in the
genome but their own. The primer sequences and acces-
sion numbers of the RGs are listed in Table 1.
The amplification mixtures contained 1.0 µl of 1:5
diluted cDNA template, 6.25 µl SYBR Green PCR Mas-
ter Mix Buffer (BioRad, Hercules, CA, USA), and 10
pmol forward and reverse primers in a final volume of
12.5 µl. The cycle conditions were as follows: an initial
incubation of 95°C for 5 min and then 45 cycles of 95°C
for 30 s and 60°C for 30 s, during which the fluores-
cence data were collected. Following amplification, a re-
action product melt curve was obtained to provide evi-
dence for a single reaction product. The iCycler iQ
Optical System Software (version 3, BioRad Labora-
tories) was used to determine the melting temperatures
of the products. The threshold cycle (Ct) value was cal-
culated as the cycle where the fluorescence of the sam-
ple exceeded a threshold level. Tumor and matched nor-
mal samples were always analyzed in the same run to
exclude between-run variations and each sample was
studied in duplicate. The stability between duplicates
was evaluated by taking the standard deviations of the
average differences of all duplicate pairs (95% CI, −0.3 ±
0.8, n = 984). A no-template control of nuclease-free
water was included in each run. The RNA samples used
for cDNA synthesis were also used for (−)RT control
(no reverse transcriptase enzyme) reactions. These nega-
tive RT-PCR controls were also included in the PCR
reactions for each set of primers. No genomic DNA con-
tamination was detected.
Data Retrieval and Selection of Candidate Reference
Genes From Microarray Studies
Two publicly available independent microarray gene
expression data sets GDS2635 (43) and GDS2250 (44)
were downloaded from the Gene Expression Omnibus
(GEO, http://www.ncbi.nlm.nih.gov/geo/) and processed
by the BRB-ARRAYTOOLS (Biometric Research Branch
[http://linus.nci.nih.gov/BRB-ArrayTools.html]. Both of
the datasets were generated by using the Affymetrix
HGU133 Plus 2.0 platform; thus, they were highly com-
parable. These two independent microarray datasets
(GDS2635 and GDS2250) were combined with respect
to gene names using a set of customized Perl routines
and the genes that were stably expressed between tumor
and normal samples were selected by using Student’s t-
test (p > 0.99). A total number of 12 normal and 45 tu-
mor samples and 54,674 gene probes were used in this
analysis. TTC22 was one of the top ranked nondifferen-
tially expressed genes between tumor and normal sam-
ples (p > 0.99) and was selected as a candidate RG.
The GDS2635 dataset is the only available dataset
that was generated by using matched normal breast tu-
mor samples. Therefore, we used this set independently
and determined the genes that showed no expression dif-
ferences between tumors and matched normal samples
by using paired Student’s t-test (p > 0.99). IL22RA1 and
ZNF224 were selected from the list as top ranked genes
and used as candidate RGs (p > 0.99).
Data Analysis
The PCR efficiencies (E) were evaluated by 10-fold
dilution series of cDNAs (1–1:100 000 dilution) for
each pair of primers by using a breast carcinoma cell
line cDNA pool (MCF7, MDA-MB-231, T47D, HMEC,
MCF12A). The primer amplification efficiencies were
also tested with reference genes ACTB, GADPH, and
SDHA in breast tumor tissue cDNA pools (n = 3) to en-
sure no inhibitory component was present in the tissue
samples. No inhibitory effect was observed in amplifica-
tion efficiencies (E = 2.0). A graph of threshold cycle
(Ct) versus relative log10 copy number of the calibration
sample from the dilution series was produced and the
reaction efficiency was determined for each primer set
by using the slope of this graph (E = 10(−1/slope)) and pre-
sented at Table 1 (45). The amplification efficiency of
each primer pair was corrected accordingly (2).
The gene expression level of GSN was normalized
with respect to RGs and expressed as the ratio of ∆Cts
[(Etarget)∆CtTarget (control−sample)/(Eref)∆CtReference (control−sample)] using the
corresponding normal pair as a control (2). When the
GSN normalization was based on multiple RGs, the geo-
metric mean of RG Ct values was applied as NF. The
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Table 1. Information on the Gene-Specific Primers and Their Real-Time PCR Efficiencies
Accession No./
Gene Primer Sequence Amplicon PCR Exon–
Symbol Gene Name (5′–3′) Size (bp) Efficiency* ExonCrossing
ACTB Beta-actin NM_001101 124 1.97 yes
Forward ccaaccgcgagaagatgacc
Reverse ggagtccatcacgatgccag
GAPDH Glyceraldehyde-3-phosphate dehydrogenase NM_002046 143 2 yes
Forward ggctgagaacgggaagcttgtcat
Reverse cagccttctccatggtggtgaaga
TBP TATA box binding protein NM_003194 132 1.97 yes
Forward tgcacaggagccaagagtgaa
Reverse cacatcacagctccccacca




HPRT Hypoxanthine phosphoribosyltransferase I NM_000194 112 2 yes
Forward gctgacctgctggattacat
Reverse tcccctgttgactggtcatt
HMBS Hydroxymethylbilane synthase NM_000190 64 2.3 yes
Forward ggcaatgcggctgcaa
Reverse gggtacccacgcgaatcac
B2M Beta-2-microglobin NM_004048 132 1.9 yes
Forward atgagtatgcctgccgtgtga
Reverse ggcatcttcaaacctccatg
PPIA Cyclophilin A NM_021130 229 1.9 yes
Forward cgtgtgctattagccatggt
Reverse ccattatggcgtgtgaagtc
GUSB Glucuronidase, beta BC014142 157 1.9 yes
Forward caccagcgtggagcaagaca
Reverse ggctgacacctggcacctta





PGK1 Phosphoglycerate kinase NM_000291 195 1.9 yes
Forward aaccagaggattaaggctgc
Reverse gcctacacagtccttcaaga
GSN Gelsolin NM_198252 108 2.0 yes
Forward ttcgagtcggccaccttcct
Reverse tctgcaccaccacctcgttg
RPL41 Ribosomal protein L41 NM_001035267 248 2.0 yes
Forward aagatgaggcagaggtccaa
Reverse tccagaatgtcacaggtcca
PUM1 Pumilio homolog 1 (Drosophila) NM_001020658 104 2.0 yes
Forward ttcacagacaccacctcctt
Reverse ctggagcagcagagatgtat
RPLP0 Ribosomal protein, large, P0 NM_053275 194 1.9 yes
Forward tcatccagcaggtgttcgac
Reverse agacaaggccaggactcgtt





Gene Primer Sequence Amplicon PCR Exon–
Symbol Gene Name (5′–3′) Size (bp) Efficiency* ExonCrossing
TTC22 Tetratricopeptide repeat domain 22 NM_017904 150 1.9 yes
Forward agtgctgaagtccgaggacc
Reverse ttgccgaagcagtctagagg
IL22RA1 Interleukin 22 receptor, alpha 1 NM_021258 177 1.9 yes
Forward ccacttagagctccaggtca
Reverse tctggcagtgtcttcactcg
ZNF224 Zinc finger protein 224 NM_013398 186 1.9 yes
Forward agaacttcaggaacctgctc
Reverse ggaaggaccactcttgatgt
18S rRNA 18S ribosomal RNA NR_003286 154 2.0 no
Forward aaacggctaccacatccaag
Reverse cctccaatggatcctcgtta
*PCR efficiencies were calculated according to Rasmussen (45).
statistical analyses were performed using Minitab soft-
ware. The two-tailed paired Student’s t-test was used
when comparing tumor and matched normal expression
values; and values of p < 0.05 with Bonferroni correc-
tion were considered statistically significant. One-way
ANOVA was performed to investigate whether tumor
samples, which were normalized to their matched nor-
mal counterparts, differed in terms of grade, estrogen
(ER), and progesterone receptor (PR) status and the ef-
fect of the age at diagnosis was analyzed with regression
analysis. Bonferroni correction was performed when
multiple tests were applied.
The software geNormTM, version 3.4 (9) and Norm
Finder (25), both Visual Basic Applications (VBA) for
Microsoft Excel, were used to calculate the stability of
candidate RGs and to find the best normalizer(s) for a
given set of reference genes. Ct values were converted
to linear expression quantities by E−∆Ct to investigate the
genes in geNorm and NormFinder. Tissue samples were
categorized into normal (n = 23) or tumor groups (n =
23) according to standard histopathological examina-
tions for the NormFinder analysis.
RESULTS
Expression Patterns of Candidate RGs
Expression levels of 18 candidate RGs were deter-
mined in 23 breast tumor tissues and their matched nor-
mal samples by qRT-PCR using the SYBR Green I dye
detection system. Amplification efficiencies calculated
based on standard curves from the serial dilutions of
breast cancer cell lines indicated that all primer pairs
were over 90% efficient (values ranged between 1.97
and 2.3) (Table 1). Each RG had a different expression
range between the tumors and matched normal samples.
The RG expression levels displayed a wide range of Ct
values between 13 and 33, grouped into three ranges for
their mean Ct values. Highly expressed genes were
B2M, ACTB, PPIA, RPL41, RPLP0, and GAPDH (mean
Ct values below 20 cycles). Genes with moderate ex-
pression were YWHAZ, PGK1, SDHA, PUM1, MRPL19,
and GUSB (mean Ct values between 20 and 25 cycles).
Genes with low expression were TBP, HPRT, IL22RA1,
TTC22, ZNF224, and HMBS (mean Ct values over 25
cycles).
The stability between duplicate measurements of each
RG used in the study was very high (95% CI, −0.3 ± 0.8,
n = 984), suggesting high experimental measurement ac-
curacy.
RGs used in this study did not exhibit differences in
terms of grade, ER, PR status (p > 0.05), or age (R 2 =
0.001 to 0.139; p > 0.05) in breast cancer. Furthermore,
raw Ct values of the 18 RGs were found to be moder-
ately to highly correlated with each other (p < 0.05,
Pearson’s correlation coefficient range 0.516–0.929, n =
46).
The reference genes used in our panel exhibited rela-
tively higher expression in tumor samples than in their
normal counterparts (paired t-test; p < 0.05). Seventeen
out of 18 reference genes displayed a consistent 1.86 ±
0.7 (log2, mean ± SD) fold expression difference be-
tween breast tumor and normal pairs. The expression
range of candidate genes was shown in terms of differ-
ence between the Ct values of tumor and normal sam-
ples as box-whisker-plots (Fig. 1).
Expression Stability of Candidate RGs
The expression stability of each gene was validated
using two different software programs, geNorm and
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Figure 1. Expression range of differences between the Ct values of breast tumor and normal samples for each candidate reference
genes. Threshold cycle values (CtTumor−Ctnormal) for each reference gene are shown as medians (lines), 25th to 75th percentile
(boxes), and range (whiskers). Whiskers illustrate the data points in Q3+1.5 (IQR) and Q1−1.5(IQR) [interquartile range (IQR) =
Q3−Q1). p-Values were calculated using the paired Student’s t-test (p < 0.05, significant). ACTB, p = 8.7 × 10−6; SDHA, p =
5.7 × 10−5; B2M, p = 0.001; PPIA, p = 4.7 × 10−6; GUSB, p = 0.000; PGK1, p = 1.0 × 10−6; YWHAZ, p = 1.0 × 10−6; TBP, p =
0.000; GAPDH, p = 4.3 × 10−8; HPRT, p = 1.9 × 10−7; HMBS, p = 8.2 × 10−5; PUM1, p = 0.000; MRPL19, p = 0.000; RPL41,
p = 0.005; RPLP0, p = 0.036; TTC22, p = 3.5 × 10−7; ZNF224, p = 0.001; IL22RA1, p = 0.358. *The Ct values that fall beyond
the whiskers.
NormFinder, to identify the most suitable genes for nor-
malization.
The geNorm program determines the most stable
RGs from a set of investigated genes in a given set of
samples. It calculates the gene expression stability mea-
sure (M) for an RG, considering the average pair-wise
variation of all other tested RGs (9). The lowest M value
marks the gene(s) with the most stable expression. The
average M value of the 18 candidate RGs are plotted in
Figure 2A. The curve represents the stepwise exclusion
of the least stable genes with higher M values. This re-
sult led to the identification of the two most stable
genes, ACTB and SDHA, in the tested samples (M =
0.7).
In addition to the stability value M, pair-wise varia-
tions (Vn/n + 1) were calculated to determine the effect
of adding a gene (n + 1) in normalization (Fig. 2b). This
allowed for determination of an NF needed to define the
optimal number of RGs required for reliable normaliza-
tion. A large pair-wise variation means that the added
gene has a significant effect on normalization and
should therefore be included for calculation of reliable
normalization (9). The most stable six genes, ACTB,
SDHA, TBP, PGK1, GUSB, and MRPL19 yielded a V
value of 0.147, giving the cut-off value 0.15.
We also used the NormFinder software program for
stability evaluation among the candidate RGs. Norm
Finder is an add-in for Microsoft Excel and is used for
calculating a stability value from a set of candidate RGs.
In this program, the stability value is based on the com-
bined estimate of inter- and intragroup expression varia-
tions of the studied gene. The candidate gene with the
smallest variability value has higher stability as it shows
the lowest variability of inter- and intragroup expression
(25). NormFinder also ranks the set of candidate RGs
according to their expression stability from a panel of
candidate genes that could be organized in different sub-
groups (tumor and matched normal tissues). Our find-
ings indicated that the genes occupying the top five
ranks, SDHA, ACTB, MRPL19, TBP, and GUSB ap-
peared to be the most stable genes, while IL22RA1 was
defined as the least stable gene (Table 2). Although Norm
Finder selected SDHA as the most stable gene with a
stability value of 0.135, the best combination of the two
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Figure 2. Selection of reference genes for normalization in breast tumor samples using geNorm analysis. (A) The curve represents
the stepwise exclusion of the least stable genes according to the M values calculated by geNorm. The genes with the higher M
values are eliminated and the remainders represent the two most stable genes, SDHA and ACTB. The genes are ranked on the x-
axis from left to right according to their expression stability. (B) Determination of the optimal number of reference genes for
normalization by calculation of the pair-wise variation (V) of normalization factor ratios for different numbers of control genes.
Each number on the bars shows the pair-wise variation between two sequential normalization factors. On the left-most side is the
pair-wise variation when the number of genes is enlarged from 2 to 3 (V2/3). Stepwise inclusion of less stable genes generates
the next data points. Inclusion of the third and the fourth genes (V4/5) nears the V value to the cut-off value of 0.15.
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Table 2. Rank of Candidate Reference Genes According





















Best two gene combination ACTB and SDHA 0.089
The candidate reference genes are listed with decreasing expression
stability from 1 to 18. The best combination of the two genes and the
stability value were calculated by NormFinder.
genes selected by the program, ACTB and SDHA, im-
proved the stability value to 0.089, indicating a more
reliable normalization.
Assessment of Suitable RGs for Normalization
GSN is an actin depolymerizing factor acting as the
principal intracellular and extracellular actin-severing
protein. Expression of GSN was shown to be undetect-
able or greatly reduced in invasive human breast carci-
nomas both at the protein and RNA level (46). The pro-
gressive loss of GSN from benign mammary tissue
through different stages of mammary tumorigenesis has
also been demonstrated (47,48). To assess the signifi-
cance of the selected RGs for normalization, the expres-
sion level of GSN mRNA was measured by qRT-PCR
and statistically evaluated in the same set of tumor and
matched normal breast tissue samples. Because a gene
expression NF could either be based on a single gene or
a combination of gene expression values (9), GSN gene
expression levels were normalized using the RGs pro-
posed by the geNorm or NormFinder calculations (i.e.,
ACTB, SDHA, GUSB, MRPL19, TBP, and PGK1 in
combinations) (Fig. 3). We also tested the performance
of IL22RA1, the lowest ranked gene both in the geNorm
and NormFinder analyses, for GSN normalization (Fig.
3). The median GSN expression values were below zero,
which indicated downregulation with respect to matched
normal GSN expression, independent of the NF used.
Moreover, statistical analyses indicated that the GSN
expression was significantly downregulated in tumor
samples when compared with that from normal samples
with combinational use of the best RGs (ACTB and
SDHA) proposed both by the geNorm or NormFinder
programs (p < 0.05). In contrast, downregulation of the
GSN expression was not significant when the least sta-
ble gene, IL22RA1, was used as NF (p > 0.05) with on
average 39% of the tumor samples being upregulated
with respect to their normal counterparts (Fig. 3). In ad-
dition, when GSN expression in tumors was not normal-
ized with RGs but normalized only with the correspond-
ing normal GSN expression [∆Ct; Ct(GSN tumor) − Ct(GSN normal)],
the expression difference was not significant between
tumor and normal pairs (0.18 ± 2.2, mean ± SD; p = 0.7,
one-sample t-test). Fold change values in GSN expres-
sion obtained by using different NFs were significantly
correlated with each other, yet the degree of correlation
increased when two genes (in combination ACTB and
SDHA) were used as NF. For example, the correlation
coefficient between tumor samples’ GSN expression val-
ues normalized with ACTB and those with SDHA (rA vs. S)
was 0.80 whereas the degree of correlation increased
when a combination of best two RG was used (rAS vs. A =
0.95 and rAS vs. S0.96, where A and S refer to ACTB and
SDHA, respectively). The addition of the third or the
fourth gene to the best two genes did not change the
correlation results more than 1% (rAS vs. ASM = 0.96 and
rAS vs. AST = 0.97, rAST vs. ASTP = 0.97).
Evaluation of 18S rRNA to mRNA Ratio
In the present study we quantified 18S rRNA, ACTB,
and SDHA mRNA levels in a group of 13 tumor and
normal pairs. The mean expression of 18S rRNA was
found to be downregulated in tumor samples (9/13)
compared to their normal counterparts (log2 difference,
1.16 ± 1.06; mean ± SD) while the expression of ACTB
and SDHA genes were consistently high in tumor sam-
ples compared to their normal pairs (log2 difference,
1.9 ± 1.4 and 1.8 ± 1.5, respectively; mean ± SD). Our
results showed that the 18S rRNA to ACTB or SDHA
mRNA ratio was approximately eightfold lower in tu-
mors than that of normal pairs on average (paired t-test
p = 4.2 × 10−5 and p = 2.2 × 10−4, respectively) (Fig. 4).
DISCUSSION
To our knowledge this is the first systematic compari-
son of frequently used RGs and their utility as internal
controls for accurate relative gene quantification in tu-
mor and matched normal breast tissue samples for qRT-
PCR studies.
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Figure 3. The normalization of GSN gene expression with combinations of candidate reference genes in tumor and matched
normal breast samples. The gene expression level of GSN in 23 tumor and normal samples was normalized with respect to an
individual RG or combinations of RGs and displayed as a box plot of [(Etarget)∆CtTarget (control-sample)/(Eref)∆CtReference (control-sample)] using matched
normal samples as controls. ACTB (A), SDHA (S), GUSB (G), MRPL19 (M), TBP (T), and PGK1 (P) individually or in combina-
tions of two or more gene combinations of the above RGs are used as NFs. GSN normalization by the lowest ranking RG,
IL22RA1 was performed. p-Values were calculated using the paired Student’s t-test (p < 0.05, significant). ACTB, p = 0.003;
SDHA, p = 0.009; AS, p = 0.005; ASM, p = 0.008; AST, p = 0.008; ASTP, p = 0.007; ASMG, p = 0.014; ASMGT, p = 0.014;
ASTPG, p = 0.010; ASTPGM, p = 0.012; IL22RA1, p = 0.236.
We took the following measures to increase the accu-
racy and reliability of our data in this study: 1) matched
pairs of normal and tumor breast samples were used for
minimization of inter-individual variation and to in-
crease the power of data analysis; 2) total RNA was
assessed stringently and only the high-quality samples
were included in the study; 3) the 18 candidate RGs
were simultaneously analyzed with optimized condi-
tions; 4) the tumor and normal matched samples were
included in the same run in duplicates for a studied
gene; and 5) established software combined with statisti-
cal analysis was used to rank the candidate RGs for their
suitability as NFs. Additionally, we showed that the ex-
pression of the RG set in breast tumors did not exhibit
differences in terms of grade, ER, or PR status and age
of the individuals when normalized to their matched
controls. This is important in clinical use because the
selected RGs can be used in all malignant samples inde-
pendent of the tested clinical parameters.
In this study, we analyzed 15 of the commonly used
RGs and 3 newly selected candidates to find out the
most suitable ones as NF for relative gene quantification
in paired breast tumor/normal gene expression profiling.
The candidate reference genes used in this study have
independent functions in cellular maintenance. This is
important because the selection of genes that share iden-
tical biochemical pathways could bias analysis. To con-
stitute the candidate reference gene panel in this study
we first searched for the frequently used genes as refer-
ences for qRT-PCR studies in breast cancer. While
ACTB, TBP, and GAPDH were commonly used as nor-
malization factor, GUSB, B2M, and PPIA have also been
used in breast cancer studies (30–40). As a second ap-
proach we identified candidate genes, SDHA, PGK1,
HMBS, HPRT, RPL41, and YWHAZ, as being used in
different studies dealing with the identification of suit-
able reference genes for any human tissues in addition
to being also recommended by geNorm. We included
three more genes, RPLP0, MRPL19, and PUM1, in our
study as they were reported to be the stable genes in
breast cancers by two other studies that were investigat-
ing the endogenous control reference genes for gene ex-
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Figure 4. The expression levels of 18S rRNA, ACTB, and SDHA genes in tumor samples compared
to their normal pairs. The gene expression levels of 18S rRNA, ACTB, and SDHA in 13 tumor
samples were normalized with respect to that of their normal pairs [−∆Ct: −(Ct(Tumor) − Ct(Normal)] and
displayed as box plot. The 18S rRNA to ACTB or SDHA mRNA ratio was close to eightfold
lower in tumors than that of normals. The significance in this difference was calculated by paired
the Student’s t-test. p-Values were found to be 4.2 × 10−5 for ACTB versus 18S rRNA and 2.2 ×
10−4 for SDHA versus 18S rRNA (p < 0.05, significant).
pression normalization in breast cancer (41,42). The
genes, TTC22, ZNF224, and IL22RA1, that were se-
lected by analyzing the publicly available breast cancer
microarray data sets were also included in the panel as
new candidate reference genes.
Our findings indicated that raw Ct values obtained
from this RG set were highly correlated with each other,
although they were not necessarily functionally related.
On the other hand, the raw Ct values obtained by using
a set of randomly primed cDNA samples showed that
although the correlation between two RNA polymerase
II transcribed genes, ACTB and SDHA, was still reserved
(r = 0.8, p = 0.001), the correlation of expression from
either of these two genes with the RNA polymerase I
transcribed 18S rRNA gene expression was not signifi-
cant (r = 0.034, p = 0.912; r = 0.206, p = 0.499). Con-
cordant with these results, the previous studies indicated
that a large number of housekeeping genes transcribed
by RNA polymerase II behaved similarly among them-
selves (29,42), which may explain the possible reason
for this correlation.
All the RGs studied here exhibited relatively higher
expression in tumors than their normal counterparts.
Similarly, it was reported that breast biopsy samples ex-
hibited great intra- and interindividual variability and
mean expression values of tumors measured in copy
numbers were greater than those of their normal coun-
terparts (14). Because of the extensive variability in RG
expression, total RNA-based (or mRNA copy numbers
when available) normalization was suggested as an NF
for tumor samples (1,14). However, because total RNA
is represented mostly by rRNA (>90%), even a small
decrease in rRNA expression may lead to a dispropor-
tional increase in the mRNA pool estimation (49,50).
Moreover, studies have shown that rDNA genes were
methylated in breast and ovarian cancers when com-
pared with those of normal controls (51,52). In fact, our
finding of low tumor rRNA to mRNA ratio suggests that
normal and tumor samples are heterogeneous in total
RNA fractions. We found that 69% of breast tumors (9/
13) exhibit dramatically lower expression of 18S rRNA
compared to their nontumor pairs, while mRNA expres-
sion of widely used housekeeping genes ACTB and
SDHA in the same set of tumors was higher (84%, 11/13).
These recent findings suggest that normalization
based on a proper set of endogenous RGs obtained from
equal amounts of total RNA/input material might be the
optimal approach for comparing tumor specimens. Our
findings indicated that estimation of mRNA from total
RNA represented an important issue requiring further
investigation in qRT-PCR studies. Because rDNA hy-
permethylation holds considerable possibility in breast
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tumors and total RNA is largely made up of rRNA, the
use of poly(A)+ RNA as a starting material may be an-
other approach for studying tumor and their matched
normal samples.
In order to increase the reliability of the endogenous
RG selection process, we analyzed the expression stabil-
ity of the 18 selected RGs with two different statistical
models: a pair-wise comparison model, geNorm, and an
ANOVA-based model, NormFinder. The results ob-
tained from the two programs were consistent for the
most and least stable gene selection. ACTB and SDHA
were found to be the most stable RGs while IL22RA1
was the least stable among the 18 genes selected for
these analyses.
Seventeen out of 18 reference genes in our panel dis-
played a consistent 1.86 ± 0.7 (log2, mean ± SD) fold
expression difference between breast tumor and normal
pairs, suggesting that there might be a more generalized
mechanism reflected in the breast samples. One possibil-
ity is that all these genes, although with unrelated func-
tions and chromosomal locations, are upregulated in tu-
mors but, considering many of these genes have been
reported previously as stable housekeeping genes, such
global deregulation is unlikely. Alternatively, tumor and
normal samples might consist of heterogeneous rRNA
and mRNA compartments affecting estimation of the
amount of mRNA from the total RNA pool. In support
of this possibility we found that a significant portion
of tumors had lower levels of 18S rRNA than normals.
Furthermore, recent literature has supported our finding
such that RNA hypermethylation has been shown in
breast tumors (52).
Recent studies suggested that the variation in the av-
erage of multiple genes was smaller than the variation
in individual genes. Therefore, it is an optimal approach
to use multiple RGs rather than a single gene as NF.
Normalization to geometric mean of more than one con-
trol gene compensates for outlying values of single RGs
in individual samples and may therefore more accurately
reflect transcript abundances of target genes (9).
Our results suggested that increasing the number of
RGs stabilized the ranks of tumor samples among nor-
malized gene expression values yet adding a third gene
was not as critical as adding the second gene. This is in
accordance with the findings of Vandesomple et al., who
state when NFn and NFn+1, where n represents the num-
ber of genes used in normalization, do not significantly
differ in their effect, using NFn might offer a more eco-
nomical choice (9). Accordingly, two best genes ACTB
and SDHA can be used as NF, and additionally more
genes, MRPL19, GUSB, TBP, and PGK1, identified by
both programs might be combined with the two best
genes to be used as NF.
In the present study, we compared the expression val-
ues of the gelsolin gene by using single or different
combinations of the best ranked RGs. When the GSN
expression was normalized with ACTB and SDHA alone,
the fold change values were significantly correlated with
each other, yet the degree of correlation increased when
two best performing genes ACTB and SDHA were used
as NF. Addition of more best performing RGs (MRPL19,
GUSB, TBP, and PGK1) did not improve the degree of
correlation results more than 1%.
GSN expression is known to decrease in breast tu-
mors when compared with normal breast tissues. The
adverse effect of using the least stable RG (IL22RA1)
was highly significant, and there was a substantial error
associated with the estimation of the relative GSN gene
expression in breast tumors compared to their normal
counterparts.
Considering that the housekeeping mRNA expression
studied here might not actually be unregulated but over-
estimated due to a rRNA bias, exclusion of this bias may
actually correct the potential underestimation of mRNA
amount estimation between tumors and their matched
normals. We calculated this possible error as 1.16 (log2
difference) for tumor–nontumor bias from the expres-
sion data obtained by using 18S rRNA from randomly
primed subset of tumor–nontumor pairs. Seventeen out
of 18 RGs in our panel displayed on average, a 1.86-
fold expression difference between tumor and normal
pairs, of which 1.16-fold might be attributable to rRNA/
mRNA bias. If RG normalization is not performed, then
it is likely that GSN expression in tumors would be over-
estimated at least 1.16-fold.
Real-time RT-PCR is attractive for clinical use be-
cause it can be automated and performed on a variety of
tissues, fresh or archived, paired or unpaired. However,
accurate quantitative analysis of gene expression levels
with qRT-PCR can only be obtained by using appro-
priate RGs for normalization procedures. As no uni-
versal RG exists, it is inevitable to search for stably
expressed genes for normalization purposes in each ex-
perimental condition, such as tumor versus normal
breast specimens, to get reliable results from relative ex-
pression experiments (22,23,27).
The present study focused on identification of RGs
for paired tumor/normal breast tissue based on the rank-
ing agreement between commonly referred normaliza-
tion software, geNorm and NormFinder, and expression
results of GSN, a well-known downregulated target gene
in breast tumors. Although this panel is highly compre-
hensive and consists of frequently used reference genes,
they may still not be the best applicable reference genes
for breast cancer normalization studies unless there is a
bias due to RNA estimation or breast tissue heterogene-
ity because all the genes in our panel showed higher
expression in tumors than in their normal pairs. How-
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ever, ACTB and SDHA were consistently found to be the
least variable genes between tumor and normal pairs
with two programs, geNorm and NormFinder, in this
panel.
In conclusion, our results indicated that normalization
of target gene expression levels to a normalization factor
consisting of the geometric mean of two best performing
genes, ACTB and SDHA, offers increased accuracy and
resolution in the relative quantification of gene expres-
sion in breast tumors with respect to their matched nor-
mal tissues. Future studies are needed to establish the
percentage of tumors with such rRNA/mRNA bias and
the underlying causes such as methylation patterns of
rDNA.
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